For example, inhibition of IL-4 and IL-13 is the main goal of dupilumab, an IgG monoclonal antibody used in the treatment of inadequately controlled AD, targeting the IL-4 receptor alpha subunit, thus inhibiting the IL-4 and IL-13 pathways [22]. This evidence concerns the gene IL4 and Alzheimer disease.